Corrigendum to 'Toll-like receptors in immunity and inflammatory diseases: Past, present, and future' [International Immunopharmacology 59 (2018) 391-412].

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Extraction and immunomodulatory activity of the polysaccharide obtained fromFrontiers in nutrition · 2022
   Article
2. Combined Photodynamic and Photothermal Therapy and Immunotherapy for Cancer Treatment: A Review.International journal of nanomedicine · 2022
   Review
3. The Absence of Toll-Like Receptor 4 Mildly Affects the Structure and Function in the Adult Mouse Retina.Frontiers in cellular neuroscience · 2019
   Article

Corrections and comments

• Erratum for
  Toll-like receptors in immunity and inflammatory diseases: Past, present, and future.2018

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.